CLAIMS:

1. An aqueous pharmaceutical composition, wherein the composition comprises:
   (a) 45 to 55 mg/ml adalimumab;
   (b) 5 to 50 mM acetate buffering agent (or acetate buffer system);
   (c) 150 to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and
   (d) 0.9 to 1.1 mg/ml polysorbate 80; and

   wherein the composition:
   - has a pH between 5.1 and 5.3;
   - is free of arginine;
   - is free of phosphate buffering agents;
   - is free of amino acids; and
   - is free of surfactants, with the exception of polysorbate 80.

2. The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is sucrose.

3. The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is trehalose.

4. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the sugar stabiliser at a concentration of 190 to 300 mM.

5. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the sugar stabiliser at a concentration of 210 to 300 mM.

6. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the acetate buffering agent (or acetate buffer system) at a concentration of 5-14 mM.

7. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the acetate buffering agent (or acetate buffer system) at a concentration of 10 mM.

8. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the acetate buffering agent (or acetate buffer system) at a concentration of 14-50 mM.

9. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the adalimumab at a concentration of 50 mg/mL.

10. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition is either free of sodium chloride or comprises sodium chloride at a concentration of from 25 mM to 75 mM.

11. The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises only a single non-buffering tonicifier, which is the sugar stabiliser.

12. An aqueous pharmaceutical composition, wherein the composition consists of:
    (a) 45 to 55 mg/mL adalimumab;
    (b) 5 to 50 mM acetate buffering agent (or acetate buffer system);
    (c) 150 to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and
    (d) 0.9 to 1.1 mg/mL polysorbate 80; and
    wherein the composition has a pH between 5.1 and 5.3.

13. An aqueous pharmaceutical composition, wherein the composition consists of:

(a) 50 mg/mL adalimumab;

(b) 10 mM acetate buffering agent (or acetate buffer system);

(c) 190 to 300 mM sugar stabiliser, wherein the sugar stabiliser is sucrose; and

(d) 0.9 to 1.1 mg/mL polysorbate 80; and

wherein the composition has a pH between 5.1 and 5.3.

14. An aqueous pharmaceutical composition, wherein the composition consists of:

(a) 45 to 55 mg/mL adalimumab;

(b) 5 to 50 mM acetate buffering agent (or acetate buffer system);

(c) 190 to 250 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and

(d) 0.9 to 1.1 mg/mL polysorbate 80; and

wherein the composition has a pH between 5.1 and 5.3.

15. Use of an aqueous pharmaceutical composition as claimed in any of claims 1 to 14 for the preparation of a medicament for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis.